. 33 Present addresses: agencies, professional societies and accrediting organizations that are considering the application of QMS standards and guidelines to NGS for clinical applications. These guidelines will be updated and expanded as NGS technologies evolve. Information about the continued activities of the working group is available at http://www.cdc.gov/ osels/lspppo/Genetic_Testing_Quality_ Practices/Nex-StoCT.html. We encourage collaborations and ongoing discussions among laboratories, clinicians, manufacturers, service providers, software developers, professional organizations and government agencies to ensure the quality of clinical NGS tests.
Assuring the quality of next-generation sequencing in clinical laboratory practice To the Editor: We direct your readers' attention to the principles and guidelines (Supplementary Guidelines) developed by the Nextgeneration Sequencing: Standardization of Clinical Testing (Nex-StoCT) workgroup. These guidelines represent initial steps to ensure that results from tests based on nextgeneration sequencing (NGS) are reliable and useful for clinical decision making. The US Centers for Disease Control and Prevention (CDC) convened this national workgroup, which collaborated to define platform-independent approaches for establishing technical process elements of a quality management system (QMS) to assure the analytical validity and compliance of NGS tests with existing regulatory and professional quality standards. The workgroup identified and addressed gaps in quality practices that could compromise the quality of both clinical laboratory services and translational efforts needed to advance the implementation and utility of NGS in clinical settings.
The workgroup was composed of experts with knowledge of and experience with NGS and included clinical laboratory directors, clinicians, platform and software developers and informaticians, as well as individuals actively engaged in NGS guideline development from accreditation bodies and professional organizations. Representatives from US government agencies also participated.
These guidelines address four topics that are components of quality management in a clinical environment: (i) test validation, (ii) quality control (QC) procedures to assure and maintain accurate test results, (iii) the independent assessment of test performance through proficiency testing (PT) or alternative approaches and (iv) reference materials (RMs). Discussions were limited to the analytic and informatics processes required for accurate variant calling. The workgroup did not address how variants are prioritized, interpreted or reported.
The workgroup recommendations are summarized in Table 1 . Although the workgroup focused on detection of DNA sequence variations associated with heritable human disorders, many of the principles and recommendations described are also relevant to the application of NGS to other areas of laboratory medicine, including the diagnosis, prognosis and treatment of cancer and infectious-disease testing.
Validation is the process of establishing analytical performance specifications for a clinical test system developed in house to confirm that the system is suitable for its intended use 1 . During the validation process, the laboratory must demonstrate that the assay functions as expected and provides • Testvalidation:establishthatthesystemcorrectlyidentifies disease-associated(andother)variantsintargetedregionsofthe genome (Supplementary Guidelines, section 4).
• Informaticspipelinevalidation:establishthatthealgorithm(s) reliably analyze platform data to produce an accurate sequence.
• Establishandvalidatealternatemethods(forexample,Sanger sequencing)toderivehigh-qualitysequencedataforproblematic genomic regions.
Quality control Document reliability of the sequence analysis during patient testing
• UtilizeacombinationofQCmaterials,bothintrinsicand/orspiked in,thatmimicgenomiccomplexityandthetypesofmutationsthe test is designed to detect.
• Duringpatienttesting,qualitymetrics(forexample,quality scores,depthanduniformityofcoverage,mappingquality,GC biasandtransition/transversionratio)shouldbeassessedand comparedtothoseestablishedduringvalidation.
• Clinicallyactionablefindingsshouldbeconfirmedbyindependent analysis using an alternate method.
Proficiency testing
Theindependent assessment of test performance
• PTchallengesshouldtargettheanalysisofbothdiseaseassociatedandnaturallyoccurringsequencevariationsacrossthe genomic regions targeted by the test to measure the reliability of sequence analysis.
• Electronicsequencefilesmaypermitacomparisonofalignment andvariantcallingmethodsacrosslaboratoriesbutwillrequire additional consideration of platform differences.
• PTprogramsshouldconsiderthedifferentgenomicregionstargeted by each recipient laboratory's assays to properly compare interlaboratory performance.
Reference materials
Theuseofmaterials for quality management of the analytical phase of testing
• RMswithbothnaturallyoccurringanddisease-associated sequencevariationsareneededfortestvalidation,QCprocedures and the independent assessment of test performance.
• SyntheticDNAandelectronicreferencedatafilesmayserveas RMsforrareorchallengingsequencevariations.
• EffortsshouldbeundertakentoestablishasuitableNGSRM andthesequenceoftheRMshouldberefinedasthetechnology changes.SuchaRMshouldbeannotatedtoindicateregionsof highandlowsequencereliability.
a SeeSupplementary Guidelinesforcompleterecommendations.RM,referencematerial.
c o r r e s p o n d e n c e npg the laboratory test, and reference range as the spectrum of nonpathogenic base changes observed in a population. Sequence variations outside this spectrum could be disease associated, but further investigation may be necessary to confirm disease association. The determination of reference range is problematic because the spectrum of sequence variations that can be defined as 'normal' or deleterious will vary across individuals and populations. QC procedures monitor whether the components of an assay-including the reagents, specimen processing, instrumentation and data processing (the informatics pipeline)-are functioning properly and delivering accurate results during testing of patient samples. The workgroup considered NGS-specific QC metrics that are useful for monitoring the performance of the assay, including: depth of coverage and uniformity of coverage, quality scores for base calling and alignment, allelic read percentage, strand bias, GC bias and decline in signal intensity (Supplementary Table 2) .
Proficiency testing and external quality assessment programs provide a formal mechanism for comparing inter-laboratory test performance and can help to identify analytical and interpretive errors and problems with QC, instrument calibration and assay design. Laboratories are encouraged to subscribe when such programs are available. PT programs typically provide several 'blinded' samples (PT challenge) to participating laboratories for analysis. The participants subsequently report their results, an interpretation and a brief description of their assay methods to the PT program. Data are compared among participating laboratories to assess inter-laboratory test performance, and a cumulative summary is shared with participants. At present, no formal PT programs exist for NGS, and development of a program faces four fundamental obstacles: (i) the absence of a defined scope for the challenge (which region(s) of the genome will be targeted); (ii) the absence of wellcharacterized PT materials suitable for a range of applications (for example, analysis of gene panels, the exome and the whole genome); (iii) the absence of standard metrics for use as comparators among participating laboratories and (iv) cost and time commitments for participants and the PT provider. To address these issues, the workgroup developed principles and guidelines for combining a formal PT challenge (when available) with an alternative assessment process, such as inter-laboratory exchange of previously characterized samples (this may include countries may also comply with the QMS standards described in ISO 15189 (ref. 3) . The performance characteristics defined in CLIA 2 and professional guidance documents 4 (ACMG standards, guidelines, and policies available at; CAP NGS checklist available to subscribers at http://www.cap.org/) do not readily translate to NGS testing practices owing to the complexity of the technology and the informatics analyses required for large-scale genome analyses. Therefore, the workgroup adapted the definitions of these performance characteristics to better fit the use of NGS in the clinical laboratory ( Table 2) . A comparison between the CLIA definitions and those developed by the workgroup is presented in Supplementary Table 1 , and the unique metrics for NGS that laboratories should establish and monitor to assure high-quality analytical results are presented in Supplementary Table 2 . For example, the depth of coverage, or the number of independent reads assessed when making a base call, is a crucial metric for establishing the accuracy, analytical sensitivity and analytical specificity of an NGS test. Owing to the high costs and extensive data analyses required for these tests, it is challenging to establish the precision (e.g., repeatability of testing replicates) of an NGS assay by determining concordance of sequencing results among a large number of samples. The workgroup proposed an alternative approach in which additional metrics such as the depth and uniformity of sequencing coverage would be incorporated to limit the number of samples required to establish precision. The workgroup redefined 'reportable range' and 'reference range' in terms of the qualitative nature of these DNA test results. This guideline classifies reportable range as the region of the genome from which sequence of an acceptable quality can be derived by reliable results. The workgroup considered the requirements of the Clinical Laboratory Improvement Amendments (CLIA) and provided recommendations for validation of clinical NGS tests. The validation process can be divided into three stages: platform, testspecific and informatics pipeline validation (Supplementary Fig. 1) . Platform validation provides evidence that the assay can deliver reliable sequence data within the regions of the genome targeted for analysis. Test-specific validation demonstrates that the assay can detect clinically important sequence variations for the intended application. Validation of the informatics pipeline establishes the software settings necessary to ensure that the test can reliably provide accurate sequence data and detect variations. Although each stage of validation is considered separately, they are interdependent. Validation requires application-specific considerations for whether the test targets a gene panel, the exome or the whole genome, as well as the types of sequence variations that are detected.
In the United States, diagnostic tests that are provided to clinical laboratories are regulated by the US Food and Drug Administration (FDA). To date, no NGS technologies have been approved or cleared by the FDA. These tests are developed in house as laboratory-developed tests and are regulated under CLIA 2 . The CLIA regulations define evaluation of analytical reliability and limitations and require laboratories to establish specifications for performance characteristics for each test system developed in house. The characteristics evaluated to establish the analytical validity of test results include accuracy, precision, analytical sensitivity, analytical specificity, reportable range, reference range or reference intervals, and other relevant performance metrics. Laboratories in the United States and other 1, 4 . RMs are homogeneous and stable, and they have the particular property being measured, such as the presence of diseaseassociated sequence variations. Many different types of samples can be used as RMs for NGS, including characterized DNA derived from human cell lines or patient specimens, synthetic DNA or electronic data. The advantages and disadvantages of each of these RMs are described in Supplementary  Table 3 . Characterization of RMs for NGS is complicated by the size of the genomic region(s) targeted for analysis. Laboratories now use gDNA obtained from a variety of sources, including human cell lines characterized in the 1000 Genomes Project 5 , to develop and validate NGS assays. However, the large spectrum of disease-associated sequence variations cannot be represented in one or any practical number of gDNA RMs. The workgroup recommended that one or more RMs that contain a combination of diseaseassociated and naturally occurring sequence variations should be evaluated for use in assay validation, QC and PT. The workgroup suggested that electronic reference data files containing real or simulated sequence data can be used for establishing and monitoring the performance characteristics of the NGS informatics pipeline. This approach is useful because combinations of DNA sequence variations can be engineered into these files to assess the capability of the informatics pipeline to make accurate variant calls. The CDC's Genetic Testing Reference Materials Coordination Program (http://wwwn.cdc.gov/ dls/genetics/RMMaterials), the US National Institutes of Health and the US National Institute for Standards and Technology are developing and characterizing RMs for NGS to meet the many needs of clinical laboratories.
C o R R E S P o N D E N C E
Sequencing technologies are evolving rapidly, and although the technical details may change, quality management requirements for test system validation, QC and PT will remain. The workgroup identified areas in which additional data collection and analysis are needed to assure the quality of clinical NGS (Supplementary Table 4) . To our knowledge, the principles and guidance developed by the workgroup are the first efforts to establish consensus among a diverse group of stakeholders. These recommendations will further inform the deliberations of regulatory
for genomic analyses, visualization should be integrated with analysis tools to enable investigators to use visualization as they work through an analysis. Integrating visualization tools with biological databases and analysis tools is a growing trend that includes genomic visualizations 3 . Genomic data visualization builds on the concept of a genome browser pioneered by Artemis 4 , popularized by University of California, Santa Cruz Genome Browser 5 , and further extended by dozens of visualization applications and frameworks that are currently in active use or development. The Integrative Genomics Viewer (IGV) genome browser 6 includes simple tools for dynamically filtering data, and the Savant browser 7 includes a framework for extending the browser to perform new visualizations and analyses. In visualization research, approaches for interacting with tool parameter spaces in applications such as computer animation 8 and image analysis 9 have been developed. These approaches use visualization as the foundation and build analysis tools on top of this foundation.
An alternative approach is to use an analysis platform as the foundation and build visualization on top of this framework. We have taken this approach by building the Trackster visual analysis environment into the Galaxy tool-integration and analysis platform (http://usegalaxy.org/) 10,11 . Trackster allows dynamic integration of tools incorporated into the Galaxy framework, including many popular tools used for high-throughput analysis. When visualizing tool output in Trackster, investigators can open the tool and modify its parameter settings, and the visualization will immediately update to reflect the new settings. Trackster also provides a parameter-space view, in which tool parameter spaces can be created and parameter sweeps can be used to systematically sample and visualize output from different parameter settings. This tight coupling of tool settings and visualization enables powerful interactions such as rapid tool parameter-space exploration and dynamic data filtering to selectively show only pertinent data. Trackster enables interactive computing by running tools only on selected data, ensuring tool run time is short even for very large high-throughput sequencing data sets. Trackster is entirely web based, requiring only a modern web browser to use all its features.
Galaxy provides a tool integration framework that allows nearly any tool (written in any language) to be integrated into Galaxy. Hundreds of tools have already been integrated in Galaxy, and there is an active community of developers continuing to do so NGS analyses by visualization with Trackster the life sciences, investigators are spending progressively more time designing and adapting pipelines to meet their needs. One particularly challenging task in the analysis of next-generation sequencing data concerns choosing the right parameters; even small changes in parameter settings can produce a remarkably different result. Trying to understand how changing analysis settings will affect the final result requires a difficult cycle of repeatedly tweaking settings, re-running the analysis many times and comparing outputs to look for differences. To make things worse, most of today's sequencing analysis tools require multiple parameter settings that change depending on experimental design, type of input data and many other factors. As a result, it is often impossible to determine a 'correct' list of settings a priori without exploring a tool's space of possible parameter values first. Exploring a tool's parameter space can become quite costly, as the size of the sequencing data sets is very large and continues to grow. Consider one of the most popular applications of today's high-throughput sequencing approaches, RNA-seq 1 . A popular approach for analyzing RNA-seq data is to use the TopHat/Cufflinks package to assemble and quantify transcripts 2 . In this approach, the quality of final assembly depends to a large degree on parameter settings chosen. Yet running the analysis requires many hours for most data sets, and hence a simple exploration of parameter settings can take days, if not weeks.
Parameter-space exploration and similar activities that require iterative analysis and data assessment suggest a new role for visualization. Rather than being an endpoint
To the Editor:
Visualization is an essential scientific tool that makes it possible to view large amounts of data simultaneously, identify patterns and outliers within data, and communicate findings to others. Data analysis and visualization have traditionally been separate: data are first analyzed, and only then is visualization used to present a graphical overview of the results. This approach breaks down, however, for large genomic data sets, for which visualizing the results of time-consuming, computationally intensive analyses often shows that different analysis settings need to be used. Repeatedly running large analyses and visualizing results is a wasteful and slow way to find good analysis settings. Visualization, then, cannot remain an endpoint for genomic analyses, but instead must be integrated with analysis tools so that it can be used to evaluate intermediate results and incrementally improve an analysis.
Here we introduce Trackster, a visual analysis environment for next-generation sequencing data that tightly couples interactive visualization with data analysis. Using Trackster, selected data subsets, rather than complete data sets, can be analyzed, thereby reducing analysis computation time from days to seconds. Trackster takes advantage of this dramatic reduction in analysis computing time to enable an interactive, visual search of analysis settings. Using Trackster, many different analysis settings can be tried quickly and the outputs from different settings visualized together, making it easy to use visual inspection to select the settings that work best-all interactively and within minutes.
As next-generation sequencing tools have been widely adopted for different uses in C o R R E S P o N D E N C E npg
